Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc.

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Highlights of Python 3.15, now available in beta, include lazy imports, faster JITs, better error messages, and smarter profiling. The first full beta of Python 3.15 ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Factorial’s solid-state batteries combine high energy density with low weight, which directly extends drone range and time on station. For commercial UAV operators, that profile supports longer ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Boston-based Factorial has landed the strategic partnership and investments it said is needed to bring a high-performing electric vehicle battery to market by 2027. Late last year, the company ...

Karma Automotive, which emerged from the remnants of Fisker Automotive, recently ended production of its range-extender Revero and is now turning its attention to a far more ambitious project. In late ...

A new partnership in battery manufacturing could help push electric vehicles closer to a long-promised breakthrough — and make EVs more practical, affordable, and appealing for everyday drivers.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...